Switch theme
Sign up to access all valuation multiples
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production and sales of in vitro diagnostic reagents and instruments.
1999
n/a
LTM Revenue $701M
LTM EBITDA n/a
$3.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Autobio Diagnostics has a last 12-month revenue of $701M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Autobio Diagnostics achieved revenue of $612M and an EBITDA of $253M.
Autobio Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Autobio Diagnostics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $612M | $669M | XXX | XXX | XXX |
| Gross Profit | $309M | $366M | XXX | XXX | XXX |
| Gross Margin | 50% | 55% | XXX | XXX | XXX |
| EBITDA | $253M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 41% | NaN% | XXX | XXX | XXX |
| Net Profit | $134M | $161M | XXX | XXX | XXX |
| Net Margin | 22% | 24% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Autobio Diagnostics's stock price is CNY 42 (or $6).
Autobio Diagnostics has current market cap of CNY 24.0B (or $3.3B), and EV of CNY 23.7B (or $3.3B).
See Autobio Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.3B | $3.3B | XXX | XXX | XXX | XXX | $0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Autobio Diagnostics has market cap of $3.3B and EV of $3.3B.
Autobio Diagnostics's trades at 4.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Autobio Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Autobio Diagnostics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.3B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | 17.3x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAutobio Diagnostics's NTM/LTM revenue growth is 17%
Autobio Diagnostics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Autobio Diagnostics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Autobio Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Autobio Diagnostics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 36% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Autobio Diagnostics acquired XXX companies to date.
Last acquisition by Autobio Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Autobio Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Autobio Diagnostics founded? | Autobio Diagnostics was founded in 1999. |
| Where is Autobio Diagnostics headquartered? | Autobio Diagnostics is headquartered in China. |
| Is Autobio Diagnostics publicy listed? | Yes, Autobio Diagnostics is a public company listed on SHG. |
| What is the stock symbol of Autobio Diagnostics? | Autobio Diagnostics trades under 603658 ticker. |
| When did Autobio Diagnostics go public? | Autobio Diagnostics went public in 2016. |
| Who are competitors of Autobio Diagnostics? | Similar companies to Autobio Diagnostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Autobio Diagnostics? | Autobio Diagnostics's current market cap is $3.3B |
| What is the current revenue of Autobio Diagnostics? | Autobio Diagnostics's last 12-month revenue is $701M. |
| What is the current EV/Revenue multiple of Autobio Diagnostics? | Current revenue multiple of Autobio Diagnostics is 4.7x. |
| What is the current revenue growth of Autobio Diagnostics? | Autobio Diagnostics revenue growth between 2023 and 2024 was 9%. |
| Is Autobio Diagnostics profitable? | Yes, Autobio Diagnostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
